Immune cells engineered to attack brain tumors enter human testing
NCT ID NCT05474378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment for adults with a returning, aggressive brain cancer called glioblastoma. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer, and delivers them directly into the brain. The main goals are to see if the treatment is safe and to find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN AND NERVOUS SYSTEM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford Cancer Institute
RECRUITINGPalo Alto, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Belly fat graft could outsmart brain Cancer's defenses
- Belly tissue used to bypass brain barrier in cancer fight
- Can ear seeds soothe your stomach and help you sleep?
- New combo therapy shows promise for older brain cancer patients
- Engineered virus takes on deadly brain cancer
- No-Mask radiation therapy: a comfortable alternative for head and neck cancer patients?